EZR (Ab-478) Antibody

What is Ezrin and what is its role in cellular function?

Ezrin (EZR) is a cytoskeletal protein that belongs to the ERM (Ezrin, Radixin, Moesin) family and functions as a cross-linker between plasma membrane proteins and the actin cytoskeleton. It plays critical roles in:

• Formation of microvilli and membrane ruffles on the apical pole of epithelial cells

• Connections between major cytoskeletal structures and the plasma membrane

• Normal macropinocytosis (alongside PLEKHG6)

• Cellular signaling pathways and cytoskeletal remodeling

Ezrin is encoded by the VIL2 gene and is also known by several aliases including Cytovillin, Villin-2, and p81 . The protein has a molecular weight of approximately 69 kDa and is involved in various cellular processes that contribute to both normal physiological functions and pathological conditions .

What specific epitope does the EZR (Ab-478) antibody recognize?

The EZR (Ab-478) antibody specifically recognizes a synthetic non-phosphopeptide derived from Ezrin around the phosphorylation site of tyrosine 478 (P-V-Y(p)-E-P). This site is crucial for Ezrin's functional activity . The antibody is designed to detect Ezrin regardless of its phosphorylation status at this specific site, making it a valuable tool for studying total Ezrin expression rather than just its activated form.

What are the primary applications for EZR (Ab-478) antibody in research protocols?

The EZR (Ab-478) antibody has been validated for multiple research applications:

The antibody has demonstrated reactivity with both human and mouse samples, making it versatile for comparative studies across species . Its polyclonal nature offers advantages in detecting multiple epitopes of the target protein.

How should researchers optimize Western blotting protocols using EZR (Ab-478) antibody?

For optimal Western blotting results with EZR (Ab-478) antibody:

• Sample preparation: Extract total protein using the Bradford method to ensure accurate quantification

• Protein loading: Load approximately 30 μg of total protein extract for consistent detection

• Gel separation: Use 10% SDS-polyacrylamide gels for optimal separation of Ezrin (69 kDa)

• Transfer: Transfer to nitrocellulose membranes at standard conditions

• Blocking: Block with specialized blocking solution (similar to LI-COR blocking solution)

• Primary antibody incubation: Dilute EZR (Ab-478) antibody 1:500-1:3000 in blocking solution and incubate overnight at 4°C

• Secondary antibody: Use appropriate species-specific secondary antibody (anti-rabbit) conjugated to desired detection method (HRP or fluorophore)

• Loading control: Reprobe with β-actin antibody to confirm equal protein loading

• Quantification: Use ImageJ software for band density quantification

This protocol has been optimized based on successful detection of Ezrin in multiple cell lines and tissues.

What considerations are important when designing experiments to study Ezrin phosphorylation using this antibody?

When studying Ezrin phosphorylation:

• Antibody selection: EZR (Ab-478) detects total Ezrin regardless of phosphorylation status at Y478. For phosphorylation studies, complement with phospho-specific antibodies

• Control treatments: Include treatments that modulate phosphorylation status:

  • Active phosphatases to reduce phosphorylation

  • Phosphatase inhibitors to maintain phosphorylation

• Activation stimuli: Consider that AKT can induce Ezrin phosphorylation through the T567 site, as observed in A549 cells

• Temporal considerations: Phosphorylation is dynamic; conduct time-course experiments

• Sample handling: Process samples rapidly with phosphatase inhibitors to prevent dephosphorylation

• Validation: Confirm phosphorylation changes with multiple techniques (WB, immunofluorescence)

Research has shown that p38α MAPK activation can lead to AKT-induced phosphorylation of Ezrin at the T567 site, which is important for Ezrin's activation and function in connecting the plasma membrane to the cytoskeleton .

What are the recommended storage and handling conditions for maintaining EZR (Ab-478) antibody activity?

For optimal performance of EZR (Ab-478) antibody:

• Storage temperature: Store at -20°C or -80°C upon receipt

• Formulation: The antibody is typically supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles which can degrade antibody performance

• Working aliquots: Prepare small working aliquots to minimize freeze-thaw cycles

• Shipping: Shipped as a liquid formulation

• Stability: Stable for at least 12 months when stored properly

• Working solution: When diluted in appropriate buffers, use within 24 hours and keep at 4°C

These storage conditions ensure the antibody maintains its immunoreactivity and specificity for experimental applications .

How can EZR (Ab-478) antibody be utilized in cancer research frameworks?

EZR (Ab-478) antibody has significant applications in cancer research:

• Expression profiling: Quantify Ezrin expression across different cancer types and stages

  • Elevated Ezrin expression has been linked to poor clinical outcomes in several cancers

• Drug resistance studies: Monitor changes in Ezrin expression after treatment with anticancer drugs

  • Research has shown increased Ezrin expression in vemurafenib-resistant melanoma and colon cancer cells carrying the BRAFV600E mutation

• Therapeutic target identification: Evaluate Ezrin as a potential therapeutic target

  • Ezrin inhibition by NSC305787 increased anti-proliferative and pro-apoptotic effects of vemurafenib in resistant cells

• Signaling pathway analysis: Study Ezrin's role in signaling pathways relevant to cancer progression

  • Ezrin inhibition has been shown to downregulate CD44 expression and inhibit AKT/c-Myc signaling in resistant cancer cells

• Metastasis research: Investigate Ezrin's role in tumor progression and metastatic spread

  • Ezrin regulates cancer-cell survival and metastatic cascade by controlling cytoskeletal remodeling

Recent research has demonstrated that pharmacological inhibition of Ezrin enhances the effects of BRAFV600E inhibitors in resistant cancer cells, indicating a potential role for combination therapy targeting both pathways .

What methodological approaches can be used to study Ezrin interactions with other proteins using EZR (Ab-478) antibody?

To study Ezrin's protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use EZR (Ab-478) antibody to pull down Ezrin and associated proteins

  • Analyze precipitated complexes by mass spectrometry or Western blotting for suspected binding partners

• Proximity ligation assay (PLA):

  • Combine EZR (Ab-478) with antibodies against potential interaction partners

  • Visualize protein-protein interactions in situ with subcellular resolution

• FRET/BRET analysis:

  • Use fluorescent/bioluminescent tagged proteins in combination with immunostaining

  • Measure energy transfer between Ezrin and potential partners

• Protein microarray analysis:

  • Apply similar principles as the KAM-1150 antibody microarray methodology

  • Use multiple antibodies to capture and detect different proteins and their interactions

• Cross-linking mass spectrometry:

  • Chemically cross-link protein complexes before immunoprecipitation

  • Identify interaction interfaces through mass spectrometry analysis

Research has identified interactions between Ezrin and CD44, which plays a role in cancer resistance mechanisms. Disrupting this interaction through Ezrin inhibition has shown promise in overcoming drug resistance in cancer cells .

How does Ezrin phosphorylation affect its detection with various antibodies, including EZR (Ab-478)?

Ezrin phosphorylation introduces important considerations for antibody-based detection:

• Epitope accessibility: Phosphorylation can alter protein conformation, potentially exposing or masking the epitope recognized by EZR (Ab-478)

• Phosphorylation-specific detection:

  • EZR (Ab-478) targets the region around Y478, but is not phosphorylation-state dependent

  • For phosphorylation studies, phospho-specific antibodies (like those detecting phospho-Ezrin at T567) should be used in parallel

• Functional states:

  • Ezrin exists in inactive (closed) and active (open) conformations

  • Phosphorylation at T567 activates Ezrin by disrupting intramolecular interactions

  • Different antibodies may preferentially detect specific conformational states

• Experimental validation:

  • Always include positive controls (cells known to express phosphorylated Ezrin)

  • Use phosphatase treatments as negative controls

Recent research has shown that AKT can induce Ezrin phosphorylation at T567, which is important for its activation in various cellular processes, including response to environmental stressors .

What are common challenges when using EZR (Ab-478) antibody and how can they be addressed?

Common challenges and solutions include:

For optimal results, researchers should follow validated protocols and include appropriate controls to validate antibody specificity in their specific experimental system.

How can researchers validate the specificity of EZR (Ab-478) antibody in their experimental systems?

To validate EZR (Ab-478) antibody specificity:

• Positive and negative controls:

  • Use cell lines with known high (SH-SY5Y cells) and low Ezrin expression

  • Include Ezrin knockout or knockdown samples as negative controls

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Signal should be significantly reduced if antibody is specific

• Multiple antibody validation:

  • Compare results with other validated anti-Ezrin antibodies targeting different epitopes

  • Consistent patterns across antibodies suggest specificity

• siRNA/CRISPR validation:

  • Generate Ezrin-depleted samples through siRNA or CRISPR

  • Signal should be significantly reduced in depleted samples

  • This approach has been used to validate anti-Ezrin antibodies in HAP1 cells

• Mass spectrometry confirmation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm protein identity in the antibody-captured material

Proper validation ensures experimental results accurately reflect Ezrin biology rather than artifacts of non-specific binding.

What controls should be included when using EZR (Ab-478) antibody in various experimental protocols?

Essential controls for experiments using EZR (Ab-478) antibody:

For Western Blotting:

• Loading control (β-actin, vinculin, or GAPDH)

• Molecular weight marker to confirm correct band size (~69 kDa)

• Positive control (cell line known to express Ezrin)

• Negative control (Ezrin-knockout cells if available)

For Immunohistochemistry/Immunofluorescence:

• Secondary antibody-only control to assess background

• Isotype control (rabbit IgG at matching concentration)

• Positive control tissue with known Ezrin expression

• Negative control (tissue not expressing Ezrin or with primary antibody omitted)

For Flow Cytometry:

• Unstained cells for autofluorescence assessment

• Isotype control (rabbit IgG monoclonal)

• Single-color controls for compensation

• FMO (fluorescence minus one) controls for gating

For ELISA:

• Standard curve using recombinant Ezrin

• Background control (no primary antibody)

• Negative control (non-Ezrin expressing sample)

Including these controls ensures accurate interpretation of results and helps identify potential technical issues.

What have recent studies revealed about Ezrin's role in cancer drug resistance mechanisms?

Recent research has uncovered important connections between Ezrin and cancer drug resistance:

• Vemurafenib resistance in BRAFV600E-mutated cancers:

  • Proteomics profiling identified Ezrin as significantly upregulated in vemurafenib-resistant colon cancer and melanoma cells

  • Increased Ezrin expression was confirmed at both gene and protein levels in resistant cells

  • The upregulation of Ezrin was time-dependent during resistance development

• Mechanism of resistance:

  • Ezrin contributes to resistance through regulation of the actin cytoskeleton organization

  • Bioinformatics analyses identified actin cytoskeleton organization as one of the most significant upregulated features in resistant phenotypes

  • Ezrin functions as a cross-linker between plasma membrane proteins and the actin cytoskeleton

• Therapeutic implications:

  • Pharmacological inhibition of Ezrin with NSC305787 synergistically enhanced vemurafenib sensitivity

  • Combined treatment significantly increased apoptosis in resistant cells

  • Ezrin inhibition was associated with downregulation of CD44 expression and inhibition of AKT/c-Myc signaling

• Translational potential:

  • Ezrin inhibition represents a potential strategy to overcome drug resistance

  • Combined targeting of BRAFV600E and Ezrin showed promising pre-clinical results

  • The combination had synergistic effects in melanoma cells and additive effects in colon cancer cells

These findings suggest Ezrin as a novel therapeutic target for overcoming resistance to targeted therapies in multiple cancer types.

How are Ezrin antibodies being used in studies of cellular responses to environmental stressors?

Ezrin antibodies are providing insights into cellular stress responses:

• Activation pathways:

  • Studies using phospho-specific and total Ezrin antibodies have revealed that environmental stressors activate p38α MAPK

  • This activation leads to AKT-induced phosphorylation of Ezrin at the T567 site

  • This phosphorylation event is crucial for Ezrin activation and cytoskeletal remodeling

• Cellular adaptation:

  • Ezrin phosphorylation status changes in response to various stressors

  • These changes facilitate cytoskeletal reorganization needed for cellular adaptation

  • Antibodies detecting different Ezrin forms help track these dynamic responses

• Disease implications:

  • Dysregulated Ezrin phosphorylation has been linked to pathological conditions

  • Studies using Ezrin antibodies have identified altered phosphorylation patterns in disease states

  • This information could inform development of targeted therapies

• Methodological approaches:

  • Combining total Ezrin antibodies like EZR (Ab-478) with phospho-specific antibodies allows tracking of both expression and activation

  • This dual approach provides a more complete picture of Ezrin dynamics during stress responses

Understanding Ezrin's role in stress responses may reveal new therapeutic approaches for conditions involving cytoskeletal dysregulation.

What new methodological developments are enhancing the use of antibodies like EZR (Ab-478) in quantitative proteomics?

Recent methodological advances are expanding antibody applications in proteomics:

• High-throughput antibody microarrays:

  • Systems like the KAM-1150 antibody microarray enable simultaneous analysis of multiple proteins

  • These platforms can measure both expression and phosphorylation states of signaling proteins

  • Quality control measures ensure consistent antibody activity and printing

• Competitive ELISA development:

  • New competitive serological ELISAs based on monoclonal antibodies offer improved sensitivity and specificity

  • Recent developments have achieved diagnostic sensitivity of 97.4-98.7% and specificity of 100% in some applications

• Advanced detection systems:

  • AlphaScreen technology allows detection of protein-protein interactions without washing steps

  • This approach uses acceptor beads coupled with antibodies and donor beads with streptavidin

  • The technique offers increased sensitivity for detecting protein complexes

• Automated platforms:

  • Systems like the Stratec Biomedical Gemini platforms enable automated ELISAs

  • These platforms improve reproducibility and throughput for antibody-based assays

• Quantification improvements:

  • Recent developments include better normalization methods to account for protein loading differences

  • Triplicate measurements enhance quantitative analysis accuracy

  • These improvements enable more reliable comparisons between samples

These methodological advances are expanding the utility of antibodies like EZR (Ab-478) in research settings, leading to more comprehensive and reliable data on protein expression and interactions.

How might EZR (Ab-478) antibody contribute to emerging therapeutic approaches targeting the cytoskeleton?

EZR (Ab-478) antibody could facilitate several emerging therapeutic approaches:

• Target validation studies:

  • Using the antibody to confirm Ezrin's involvement in disease mechanisms

  • Quantifying changes in Ezrin expression or localization in response to potential therapeutics

  • Correlating Ezrin status with clinical outcomes to identify patient populations most likely to benefit

• Combination therapy development:

  • Monitoring Ezrin status during treatment with cytoskeleton-targeting drugs

  • Identifying synergistic drug combinations that affect Ezrin-dependent pathways

  • Determining optimal timing and sequencing of combination therapies

• Biomarker development:

  • Evaluating Ezrin as a predictive biomarker for response to therapies

  • Using the antibody in diagnostic assays to stratify patients

  • Monitoring treatment efficacy through changes in Ezrin expression or phosphorylation

• Drug screening:

  • High-throughput screening for compounds that modulate Ezrin expression or function

  • Validating hits from screens using EZR (Ab-478) antibody to confirm target engagement